Cyclooxygenase-2-dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/Cxcl8 in Human Non-Small Cell Lung Cancer.
M Pold,LX Zhu,S Sharma,MD Burdick,Y Lin,PPN Lee,A Pold,J Luo,K Krysan,M Dohadwala,JT Mao,RK Batra,RM Strieter,SM Dubinett
DOI: https://doi.org/10.1158/0008-5472.can-03-3262
IF: 11.2
2004-01-01
Cancer Research
Abstract:Elevated tumor cyclooxygenase (COX)-2 activity plays a multifaceted role in non-small cell lung cancer (NSCLC). To elucidate the role of COX-2 in the in vitro and in vivo expression of two known NSCLC angiogenic peptides, CXC ligand (CXCL) 8 and CXCL5, we studied two COX-2 gene-modified NSCLC cell lines, A549 and H157. COX-2 overexpression enhanced the in vitro expression of both CXCL8 and CXCL5. In contrast, specific COX-2 inhibition decreased the production of both peptides as well as nuclear translocation of nuclear factor kappaB. In a severe combined immunodeficient mouse model of human NSCLC, the enhanced tumor growth of COX-2-overexpressing tumors was inhibited by neutralizing anti-CXCL5 and anti-CXCL8 antisera. We conclude that COX-2 contributes to the progression of NSCLC tumorigenesis by enhancing the expression of angiogenic chemokines CXCL8 and CXCL5.